Dynavax Technologies Co.

David Novack, President & COO of Dynavax, exercised 114,000 stock options and immediately sold the resulting shares for about $1.8 million, leaving him with 63,344 shares (≈0.05% of outstanding). The options exercised comprised 20,000 at $6.80 and 94,000 at $10.47, producing net proceeds of roughly $680,000 after costs. The transaction occurred as Dynavax shares traded near the $15.50 per-share acquisition price agreed with Sanofi. » Więcej na finance.yahoo.com

Dynavax agreed to be acquired by Sanofi for $2.2 billion, with an offer of $15.50 per share representing about a 39% premium to the Dec. 23 close. The deal brings Dynavax’s adult hepatitis B vaccine Heplisav-B and shingles candidate Z-1018 into Sanofi’s portfolio. Dynavax said Sanofi’s global scale will help maximize the vaccines’ commercial and development potential. » Więcej na finance.yahoo.com

Dynavax has entered a worldwide exclusive license agreement with Vaxart to develop and commercialize Vaxart’s oral COVID-19 vaccine, paying an upfront $25m plus a $5m equity stake. Vaxart remains responsible for development until completion of the ongoing Phase‑2b study; Dynavax may assume further development at the end of 2026 for an additional $50m. Milestone payments to Vaxart could total up to $620m, plus royalties on future sales; the Phase‑2b trial with about 5,400 participants is funded under Project NextGen. Dynavax is described as financially well positioned but is currently not profitable; the company also announced a new $100m share buyback program. » Więcej na de.investing.com